So what we looked at was a subgroup analysis to investigate patients who had had prior DME treatment, of which almost 44% had previous treatment for DME who were enrolled in that study.

including neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), and macular telangiectasia (MacTel). While anti-vascular endothelial growth factor (VEGF) therapies ...

The end of the line is looming for Oxurion, after a clinical trial of its last pipeline drug for diabetic macular oedema (DME) failed to meet its primary endpoint. With its cash reserves dwindling ...